GSK: Jemperli Receives U.S. FDA Breakthrough Therapy Designation for Locally Advanced DMMR/MSI-H Rectal Cancer
December 18, 2024
December 18, 2024
LONDON, England, Dec. 18 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2024:
* * *
- Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab
- Breakthrough Therapy Designation granted to drugs with potential to show improvement over available therapies for serious conditions
- Current standard of care can . . .
* * *
- Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab
- Breakthrough Therapy Designation granted to drugs with potential to show improvement over available therapies for serious conditions
- Current standard of care can . . .